Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA : NSDQ)

• Company Description    Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. Number of Employees: 77

• Price / Volume Information    Yesterday's Closing Price: $25.01 Daily Weekly Monthly 20 Day Moving Average: 1,060,245 shares Shares Outstanding: 134.42 (millions) Market Capitalization: $3,361.87 (millions) Beta: 1.56 52 Week High: $30.58 52 Week Low: $9.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.39% -15.25% 12 Week 9.55% 7.78% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3rd Floor 1 Ashley Road Altrincham - Cheshire,X0 WA14 2DT GBR ph: 1 617 468-5770 fax: - investors@centessa.com http://www.centessa.com

• General Corporate Information    Officers Saurabh Saha - Chief Executive Officer and Director Francesco De Rubertis - Chairman of the Board and Director John Crowley - Chief Financial Officer Iqbal Hussain - General Counsel Arjun Goyal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 152309100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 134.42 Most Recent Split Date: (:1) Beta: 1.56 Market Capitalization: $3,361.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 11.11 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -10.81% vs. Previous Quarter: -7.89% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -49.39 06/30/25 - -40.39 ROA 12/31/25 - - 09/30/25 - -34.64 06/30/25 - -29.87 Current Ratio 12/31/25 - - 09/30/25 - 10.56 06/30/25 - 10.11 Quick Ratio 12/31/25 - - 09/30/25 - 10.57 06/30/25 - 10.12 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,595.38 06/30/25 - -1,510.27 Book Value 12/31/25 - - 09/30/25 - 2.25 06/30/25 - 2.58 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.36 06/30/25 - 0.32 Debt-to-Capital 12/31/25 - - 09/30/25 - 26.69 06/30/25 - 24.10

Powered by Zacks Investment Research ©